128 related articles for article (PubMed ID: 16359964)
1. Procoagulant state after raloxifene therapy in postmenopausal women.
Azevedo GD; Franco RF; Baggio MS; Maranhão TM; Sá MF
Fertil Steril; 2005 Dec; 84(6):1680-4. PubMed ID: 16359964
[TBL] [Abstract][Full Text] [Related]
2. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women.
Azevedo GD; Franco RF; Baggio MS; Maranhão TM; Ferriani RA; Silva de Sá MF
Climacteric; 2003 Jun; 6(2):140-5. PubMed ID: 12841884
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
4. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
[TBL] [Abstract][Full Text] [Related]
6. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
7. The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.
Shand B; Gilchrist N; Blackwell T; March R
Clin Hemorheol Microcirc; 2002; 26(4):249-55. PubMed ID: 12122230
[TBL] [Abstract][Full Text] [Related]
8. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
10. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
[TBL] [Abstract][Full Text] [Related]
12. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
13. Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study.
Natale V; Albertazzi P; Missiroli N; Pedrini D; Salgarello M
Maturitas; 2004 May; 48(1):59-63. PubMed ID: 15223109
[TBL] [Abstract][Full Text] [Related]
14. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis.
Ando H; Otoda T; Ookami H; Nagai Y; Inano A; Takamura T; Ushijima K; Hosohata K; Matsushita E; Saito T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):227-32. PubMed ID: 23323567
[TBL] [Abstract][Full Text] [Related]
15. Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis.
Ertugrul DT; Gürsoy A; Yücel M; Sahin M; Unal AD; Pamuk B; Berberoglu Z; Aytürk S; Tutuncu NB; Demirag NG
Platelets; 2006 Sep; 17(6):351-3. PubMed ID: 16973494
[TBL] [Abstract][Full Text] [Related]
16. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
17. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
Gol M; Baris N; Guneri S; Posaci C
Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
Adomaityte J; Farooq M; Qayyum R
Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
[TBL] [Abstract][Full Text] [Related]
20. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
